Follow
Carlino Matteo S
Carlino Matteo S
Melanoma Institute Australia; Westmead Hospital
Verified email at sydney.edu.au - Homepage
Title
Cited by
Cited by
Year
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
80632015
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
61882015
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
36282017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
31812019
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis
DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ...
JAMA oncology 4 (12), 1721-1728, 2018
20572018
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ...
New England Journal of Medicine 378 (19), 1789-1801, 2018
18062018
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The lancet oncology 16 (8), 908-918, 2015
17692015
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet 390 (10105), 1853-1862, 2017
13002017
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709-717, 2017
10832017
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet Oncology 20 (9), 1239-1251, 2019
10552019
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ...
Annals of Oncology 28 (2), 368-376, 2017
8152017
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double …
GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ...
The Lancet Oncology 20 (8), 1083-1097, 2019
7022019
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...
Journal of Clinical Oncology 40 (2), 127-137, 2022
6932022
Immune checkpoint inhibitors in melanoma
MS Carlino, J Larkin, GV Long
The Lancet 398 (10304), 1002-1014, 2021
6812021
Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy
TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ...
Cancer cell 35 (2), 238-255. e6, 2019
6662019
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ...
JAMA oncology 2 (2), 234-240, 2016
6302016
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact
H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ...
Clinical cancer research 20 (7), 1965-1977, 2014
5732014
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort …
JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ...
The Lancet Oncology 19 (3), 310-322, 2018
5552018
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
AM Menzies, LE Haydu, L Visintin, MS Carlino, JR Howle, JF Thompson, ...
Clinical cancer research 18 (12), 3242-3249, 2012
5422012
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
GV Long, C Fung, AM Menzies, GM Pupo, MS Carlino, J Hyman, ...
Nature communications 5 (1), 5694, 2014
3942014
The system can't perform the operation now. Try again later.
Articles 1–20